This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

R348 (Oral)

Rigel Pharmaceuticals, Inc.

Drug Names(s): R348

Description: BioMedTracker has separate drug profiles for the oral and topical formulations of R348. Please also see R348 (Topical).

R348 is an orally available inhibitor of Janus Kinase 3 (JAK3), a cytoplasmic tyrosine kinase with expression limited to T cells, B cells, natural killer (NK) cells, mast cells, and macrophages. JAK3 acts in the signal transduction cascade of numerous growth factors used in lymphocyte activation and plays a role in lymphocyte differentiation and proliferation.


R348 (Oral) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug